Incidence of de novo Lymphoproliferative Disorders and Hematological Malignancies in Liver Transplant Recipients: An Updated Meta-Analysis.

IF 2.4 Q2 MEDICINE, GENERAL & INTERNAL

Saudi Journal of Medicine & Medical Sciences Pub Date : 2026-01-19 eCollection Date: 2026-01-01 DOI:10.4103/sjmms.sjmms_471_25

Eyad Gadour, Bogdan Miutescu, Hadi Kuriry, Camelia Nica, Ehab Abufarhaneh, Lameyaa A Alsheekh, Ehsaneh Taheri, Zahra AlSaeed, Mohammed Saad AlQahtani, Sharaf Zarrouq, Antonio Facciorusso

{"title":"Incidence of de novo Lymphoproliferative Disorders and Hematological Malignancies in Liver Transplant Recipients: An Updated Meta-Analysis.","authors":"Eyad Gadour, Bogdan Miutescu, Hadi Kuriry, Camelia Nica, Ehab Abufarhaneh, Lameyaa A Alsheekh, Ehsaneh Taheri, Zahra AlSaeed, Mohammed Saad AlQahtani, Sharaf Zarrouq, Antonio Facciorusso","doi":"10.4103/sjmms.sjmms_471_25","DOIUrl":null,"url":null,"abstract":"Background: De novo malignancies are a significant cause of mortality in liver transplant recipients. This systematic review and meta-analysis synthesized evidence regarding the incidence of de novo lymphoid and hematological malignancies.Methods: Observational studies that compared the prevalence of hematologic malignancies in liver transplant recipients with the general population were included following searches using relevant keywords in ScienceDirect, PubMed, and Google Scholar. The methodological quality of the included studies was evaluated using the Newcastle-Ottawa Scale, with the overall quality converted into the Agency for Healthcare Research and Quality standards (i.e., poor, fair, and good). The generic inverse variance method was used to pool the standardized incidence ratio (SIR) as risk ratios and their 95% confidence intervals (CI).Results: A total of 32 studies were included. Following liver transplantation, post-transplant lymphoproliferative disorder was the most common hematologic malignancy (SIR: 23.06, 95% CI: 4.08-130.04; P < 0.0004), while multiple myeloma was the least common (SIR: 3.10, 95% CI: 2.22-4.34; P < 0.0001). The incidence of non-Hodgkin lymphoma (SIR: 11.05, 95% CI: 8.54-14.28; P < 0.0001) was higher than that of Hodgkin lymphoma (SIR: 7.59, 95% CI: 5.63-11.23; P < 0.0001). The overall risk of hematologic malignancies in liver transplant recipients was significantly higher than in the general population (SIR: 5.83; 95% CI: 2.35-8.05; P < 0.0001).Conclusion: This meta-analysis found that after liver transplantation, post-transplant lymphoproliferative disorder (PTLD) is the most prevalent hematological malignancy. Although PTLD and other hematologic malignancies are less prevalent than solid organ nonlymphoid tumors, they significantly affect liver transplant recipient outcomes. Further research is necessary to identify strategies for managing these complications.Registration: PROSPERO (Reg. no.: CRD420251131279).","PeriodicalId":21442,"journal":{"name":"Saudi Journal of Medicine & Medical Sciences","volume":"14 1","pages":"23-35"},"PeriodicalIF":2.4000,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12890238/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Saudi Journal of Medicine & Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/sjmms.sjmms_471_25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: De novo malignancies are a significant cause of mortality in liver transplant recipients. This systematic review and meta-analysis synthesized evidence regarding the incidence of de novo lymphoid and hematological malignancies.

Methods: Observational studies that compared the prevalence of hematologic malignancies in liver transplant recipients with the general population were included following searches using relevant keywords in ScienceDirect, PubMed, and Google Scholar. The methodological quality of the included studies was evaluated using the Newcastle-Ottawa Scale, with the overall quality converted into the Agency for Healthcare Research and Quality standards (i.e., poor, fair, and good). The generic inverse variance method was used to pool the standardized incidence ratio (SIR) as risk ratios and their 95% confidence intervals (CI).

Results: A total of 32 studies were included. Following liver transplantation, post-transplant lymphoproliferative disorder was the most common hematologic malignancy (SIR: 23.06, 95% CI: 4.08-130.04; P < 0.0004), while multiple myeloma was the least common (SIR: 3.10, 95% CI: 2.22-4.34; P < 0.0001). The incidence of non-Hodgkin lymphoma (SIR: 11.05, 95% CI: 8.54-14.28; P < 0.0001) was higher than that of Hodgkin lymphoma (SIR: 7.59, 95% CI: 5.63-11.23; P < 0.0001). The overall risk of hematologic malignancies in liver transplant recipients was significantly higher than in the general population (SIR: 5.83; 95% CI: 2.35-8.05; P < 0.0001).

Conclusion: This meta-analysis found that after liver transplantation, post-transplant lymphoproliferative disorder (PTLD) is the most prevalent hematological malignancy. Although PTLD and other hematologic malignancies are less prevalent than solid organ nonlymphoid tumors, they significantly affect liver transplant recipient outcomes. Further research is necessary to identify strategies for managing these complications.

Registration: PROSPERO (Reg. no.: CRD420251131279).

Abstract Image

查看原文本刊更多论文

肝移植受者新发淋巴增生性疾病和血液恶性肿瘤的发病率：一项最新的荟萃分析

背景：新发恶性肿瘤是肝移植受者死亡的重要原因。本系统综述和荟萃分析综合了有关新发淋巴和血液系统恶性肿瘤发生率的证据。方法：观察性研究比较了肝移植受者与普通人群血液恶性肿瘤的患病率，并在ScienceDirect、PubMed和谷歌Scholar中使用相关关键词进行搜索。采用纽卡斯尔-渥太华量表对纳入研究的方法学质量进行评估，并将总体质量转换为卫生保健研究机构和质量标准（即差、一般和良好）。采用通用反方差法将标准化发生率（SIR）合并为风险比及其95%置信区间（CI）。结果：共纳入32项研究。肝移植术后最常见的血液学恶性肿瘤是淋巴细胞增生性疾病（SIR: 23.06, 95% CI: 4.08-130.04; P < 0.0004），而最不常见的是多发性骨髓瘤（SIR: 3.10, 95% CI: 2.22-4.34; P < 0.0001）。非霍奇金淋巴瘤（SIR: 11.05, 95% CI: 8.54 ~ 14.28; P < 0.0001）的发病率高于霍奇金淋巴瘤（SIR: 7.59, 95% CI: 5.63 ~ 11.23; P < 0.0001）。肝移植受者发生血液系统恶性肿瘤的总体风险显著高于普通人群（SIR: 5.83; 95% CI: 2.35-8.05; P < 0.0001）。结论：本荟萃分析发现肝移植后，移植后淋巴细胞增生性疾病（PTLD）是最常见的血液系统恶性肿瘤。尽管PTLD和其他血液学恶性肿瘤比实体器官非淋巴肿瘤发病率低，但它们显著影响肝移植受体的预后。需要进一步的研究来确定管理这些并发症的策略。注册：普洛斯彼罗（注册）否。: CRD420251131279)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Saudi Journal of Medicine & Medical Sciences MEDICINE, GENERAL & INTERNAL-

CiteScore

1.40

自引率

0.00%

发文量

审稿时长

15 weeks

期刊介绍： Saudi Journal of Medicine & Medical Sciences (SJMMS) is the official scientific journal of Imam Abdulrahman Bin Faisal University. It is an international peer-reviewed, general medical journal. The scope of the Journal is to publish research that will be of interest to health specialties both in academic and clinical practice. The Journal aims at disseminating high-powered research results with the objective of turning research into knowledge. It seeks to promote scholarly publishing in medicine and medical sciences. The Journal is published in print and online. The target readers of the Journal include all medical and health professionals in the health cluster such as in medicine, dentistry, nursing, applied medical sciences, clinical pharmacology, public health, etc.